第13届国际治疗药物监测和临床毒理学会议

作者:   2013-05-04
字体大小:
  • 会议时间: 2013-09-22至 2013-09-26
  • 会议地点: 美国
  • 电话:+1 613-531-8166
  • 传真:+1 613-531-0626
  • 联系人:IATDMCT Congress Secretariat
  • Email: congress@eventsmgt.com
  • 联系地址:
  • 会议网址:http://iatdmct.com/

TDM is a multi-disciplinary clinical specialty aimed at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown it improved outcome in the general or special populations.  It can be based on a a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of blood concentrations of drugs (pharmacokinetic monitoring) and/or biomarkers (pharmacodynamic monitoring).

A priori TDM consists of determining the initial dose regimen to be given to a patient, based on clinical endpoint and on established population pharmacokinetic-pharmocodynamic (PK/PD) relationships.  These relationships help to identify sub-populations of patients with different dosage requirements, by utilizing demographic data, clinical findings, clinical chemistry results, and/or, when appropriate, pharmacogenetic characteristics.

A posteriori TDMincludes pre-analytical, analytical and post-analytical phases, each with the same importance;is most often based on the specific, accurate, precise and timely determinations of the active and/or toxic forms of drugs in biological samples collected at the appropriate times in the correct containers (PK monitoring), OR can employ the measurement of biomarkers as a surrogate or end-point markers of effect (PD monitoring) e.g. concentration of an endrogenous compound, enzymatic activity, gene expression, etc. either as a complement to PK monitoring or as the main TDM tool.

编辑: 陈   

声明:

1.丁香会议频道仅负责发布会议信息,如需参会、获取邀请函或会议日程,请与主办单位联系

2.部分会议信息来自互联网,如您发现信息有误,请联系meeting@dxy.cn纠错

3.如您发现信息不全,可点击Google搜索更多

4.更多服务信息请点击这里

以下网友留言只代表网友个人观点,不代表网站观点

网友评论